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Abstract 
 
Objective: Food allergy is an increasing health problem in Westernized societies. The 
avoidance of food allergens is the unique effective treatment. Due to strict diets, these 
patients have a nutritious handicap that can compromise their normal development. Our aim 
is to organize all scientific studies that have been performed in order to outline the role and 
efficacy of Omalizumab in treatment of food allergy. Data Source: We insert our query on 
four electronic databases: Isi Web of Knowledge, Pubmed, Scopus and Embase. Study 
selection:  We performed a double blind selection of studies. Each reviewer applied the 
exclusion criteria on titles and abstracts, later they both applied the inclusion criteria on full 
text of potential eligible studies. Where the both of reviewers agreed, they either included or 
excluded the trial. Any disagreements were resolved by discussion between the reviewers. 
Results: A total of 1167 potential relevant papers were identified and 6 were included. All 
studies, unanimously, reported a general improvement of clinical status of food allergic 
patients. Almost all studies revealed a decrease of levels of total and specific IgE and also the 
wheal/erythema size in SPT. Increase of allergen threshold was demonstrated in the totality 
of included studies. Some studies concluded that the treatment with Omalizumab before OIT 
has an important impact on reduction of OIT duration. Conclusion: Omalizumab seems to be 
an important adjuvant drug for treatment of food allergy and it will potentially improve the 
quality of life of allergic food patients and of their families.  
Keywords: Omalizumab; Anti-IgE; Food allergy; Food Hypersensitivity; allergen; IgE. 
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Introduction 1 
Food allergy is an increasing health problem in Westernized societies, affecting 2 
almost 5% of young children and 3% to 4% of adults.
1
 The most common implicated food 3 
allergens are cow’s milk, egg, wheat, soy, peanut, tree nuts, fish and shellfish, although 4 
considerable geographic variation occurs according to  regional diet and cultural habits.
1, 2
 5 
Food allergy is a food-related adverse effect mediated by an immune hypersensitivity 6 
that is reproducible after an exposure to a given food.
3
 IgE-mediated food allergy is the most 7 
common and dangerous of the food hypersensitivity disorders and develops within seconds or 8 
minutes after exposure to a small quantity of food allergen. It may be manifested as acute 9 
urticaria / angioedema, atopic eczema dermatitis syndrome, oral allergy syndrome; 10 
gastrointestinal symptoms and anaphylaxis.
1
 Some less common, food hypersensitivity 11 
disorders result from non-IgE, cell-mediated mechanisms like food protein-induced 12 
proctocolitis, food protein-induced enteropathy, food protein-induced enterocolitis syndrome 13 
and Heiner’s syndrome.1  14 
Food allergy evaluation requires a careful medical history, skin prick tests, laboratory 15 
studies and, in many cases, oral food challenges (OFC) to confirm the diagnosis.
2
 Skin prick 16 
tests are the primary tool in the diagnosis of food allergy, with a negative predictive value 17 
greater than 95% (in IgE-mediated reactions) and positive predictive value ranging from 20–18 
50%, depending on the history.
1
 If the skin prick tests with commercial extracts are negative 19 
in a highly suggestive clinical history, prick-to-prick tests using fresh or native foods, 20 
especially with fruits and vegetables might be indicated, since they have proven to be more 21 
sensitive.
1
 Laboratoty tests, mainly specific IgE (sIgE) measurements might also be usefull to 22 
identify causative allergens of suspected food allergen reactions. Although specific cut-off 23 
values levels have been published (defined as 95% predictive values of positive reactions 24 
after oral challenge with the same allergen) both for skin prick tests and sIgE,
1
 none of this 25 
2 
 
methods is diagnostic of food allergy. 
3
 Actually, positive skin test or sIgE only prove allergic 26 
sensitization. Therefore, double-blind, placebo-controlled, oral food challenge is considered 27 
the gold standad test for diagnosis of food allergy.
4
  28 
Avoidance of food allergens has been the standard care for food allergic patients. 29 
Beside avoidance, patients in high risk of anaphylactic reaction should carry an emergency 30 
kit (epinephrine, oral antihistamine and glucocorticosteroids).
1, 2
 Patients, families and 31 
healthcare personal must be aware that intramuscular injection of adrenaline is the first line 32 
treatment of anaphylaxis and delayed administration of adrenaline is associated with fatal 33 
outcomes.
1, 2
 Due to their diet avoidance of specific foods, these patients are at risk nutritional 34 
imbalance that may compromise their normal development. Hence, they may benefit a 35 
nutritionist support to compensate deficiency in certain nutrients. 
1, 2
 36 
Allergen specific IgE antibodies play a central role in the pathophysiology of 37 
immediate food allergic reactions, binding to high-affinity receptors on the surface of mast 38 
cells and basophils. 
5
 leading to the release of potent mediators, mainly histamine, and 39 
synthesize new mediators (prostaglandins, leukotrienes, and cytokines).
6
  40 
Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody that 41 
binds to the IgE molecule at the same epitope on the Fc region that binds to FcεRI.7, 8 42 
Omalizumab binds to circulating IgE, regardless of allergen specificity, forming small, 43 
biologically inert IgE–anti-IgE complexes with no activity on the complement cascade. 8-10 It 44 
also induces rapid reduction in free IgE levels by down regulation of the FceRI expression on 45 
inflammatory cells (basophils, monocytes and dendritic cells).
11-13
 Omalizumab does not bind 46 
to the variable allergen specific region of IgE nor to cell-bound IgE, therefore it does not 47 
trigger degranulation of mast cells or basophils, decreasing the risk of an anaphylactic 48 
reaction. 
10, 14, 15
 Omalizumab was approved by FDA to treat allergic asthma in 2003. Since 49 
then, it has been shown that Omalizumab treatment reduces blood eosinophil levels in 50 
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patients with seasonal allergic rhinitis and asthma and sputum eosinophils in asthmatic 51 
patients. 
4
 Few studies have shown that the treatment with anti-IgE improves the 52 
symptomatology of food allergic patients. 
16, 17
   53 
The aim of this systematic review is to evaluate the role and efficacy of anti-IgE in the 54 
treatment of food allergy.   55 
 56 
Methods 57 
Search strategy 58 
We used the following electronic databases: Isi Web of knowledge, Pubmed, Scopus 59 
and Embase. To reduce the risk of losing relevant studies, searches were not restricted by 60 
language, publication type or study design. Index and / or MESH terms were combined in the 61 
following query: (food OR milk OR casein OR lactoglobulin OR fish OR egg OR nut OR 62 
wheat OR apple OR bean OR orange OR peach OR lettuce OR peanut) AND 63 
(hypersensitivity* OR allerg*) AND (anti-IgE OR omalizumab).  64 
Inclusion criteria 65 
Studies were eligible for inclusion if they met all the following criteria: 66 
1. Study design: Randomised controlled trials (RCTs), quasi-RCTs, controlled clinical 67 
trials or observational studies involving children or adults. 68 
2. Diagnosis of food allergy supported by SPT (skin prick test), specific IgE (sIgE) 69 
and/or OFC (oral food challenge). 70 
3. Treatment of food allergy with anti-IgE drugs. 71 
Exclusion criteria 72 
The following exclusion criteria were defined: 73 
1. Article written in other language than English 74 
2. Non-human studies 75 
4 
 
3. Review/ systematic review articles that do not present new original data about the 76 
subject. 77 
Data collection and analysis 78 
Two review authors independently checked and reviewed titles and abstracts of identified 79 
studies. Data extraction was independently performed by two reviewers with disagreements 80 
resolved through discussion. Quality assessment of RCTs was done according to CONSORT 81 
statement recommendations.
18
 82 
 83 
Results 84 
The last search was run on March 2013, and we obtained 1167 potential relevant 85 
papers. No additional studies were identified after screening all reference lists of the full-text 86 
papers reviewed. After all processes we obtained 6 studies that fulfilled the inclusion criteria: 87 
2 double-blind placebo-controlled studies and 4 uncontrolled trials. This selection process is 88 
depicted on flow diagram according to PRISMA.
19
  89 
Studies design 90 
Only 2 RCTs 
16, 17
 designed to evaluate the efficacy and safety of anti-IgE in food 91 
allergy treatment were found. RCT are described in table 1 and their outcomes are resumed in 92 
table 2.  Four additional non-RCTs were included, 3 published in full-text 
20-22
 and 1 reported 93 
only in resume.
23
 Table 3 resumes non-RCTs data. 94 
Diagnostic criteria of food allergy 95 
Diagnosis of food allergy was supported by a double-blind, placebo-controlled OFC 96 
and SPT with commercial extracts with the exception of the study by Nadeau et al.
20
 Specific 97 
IgE to peanut 
23
 and milk 
20
 were used in 2 studies. The main allergic symptoms described 98 
were: urticaria, angioedema, throat swelling, asthma, wheezing, and others symptoms.  99 
Anti-IgE treatment 100 
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The biggest RCT including 59 active patients and 23 controls was published by Leung et al 
17
 101 
in 2003, using an anti-IgE monoclonal antibody – TNX-901 – that has not been chosen for 102 
further development and was abandoned. Therefore the only RCT using a current available 103 
drug is the study by Samson et al
16
. This phase II trial was stopped early due to 2 104 
anaphylactic reactions that occurred in OFC before omalizumab treatment and only 14 105 
patients completed the study. A pre and post-omalizumab treatment comparison of food 106 
allergic patients was performed in 2 studies. Savage et al 
22
 evaluated 10 patients with peanut 107 
allergy treated with omalizumab for 6 months while Rafi et al 
21
 performed an observational 108 
study of the effect of omalizumab in patients with a moderate to severe asthma and 109 
concomitant food allergies.  Two uncontrolled trials aimed to address the role of omalizumab 110 
before oral immunotherapy (OIT) with foods. Henson and coworkers 
23
 evaluated 6 patients 111 
with peanut allergy and Nadeau and coworkers 
20
 11 patients with milk allergy. 112 
Outcomes 113 
Oral food challenge threshold was used as the main outcome in 5 of 6 studies. Although in 114 
both RCTs 
16, 17
 data seems to suggest an improvement in OFC tolerance, only the treatment 115 
with the highest dose (450 mg) of TNX-901 presented significant difference versus placebo.
17
 116 
Also in the uncontrolled study by Savage et al. 
22
 the dose of tolerated peanut protein on OFC 117 
increases significant after omalizumab treatment. In both uncontrolled studies evaluating 118 
omalizumab as an adjunctive treatment of OIT 
20, 23
 there seems to be a positive effect with 119 
most patients reaching the predefined maintenance dose. 120 
A significant reduction in SPT mean flare is reported by Savage et al.
22
 Total free IgE levels 121 
presents a significant post-treatment decrease in both RCTs. 
16, 17
 122 
Safety data is reports in all studies. Omalizumab was well tolerated in food allergic patients 123 
and no drug-related severe reactions were reported. Severe reactions reported, especially in 124 
6 
 
the study by Sampson et al. 
16
 that lead to premature interruption of the trial were related to 125 
food allergy reactions and not to anti-IgE treatment. 126 
Quality assessment of RCTs reports is acceptable. 127 
 128 
Discussion 129 
In this systematic review we have evaluated the role of anti-IgE treatment in food allergy. 130 
Although there is still very limited data, all included studies support the concept that anti-IgE 131 
may have role as an additional treatment in food allergy and as a facilitator of oral 132 
immunotherapy with foods. 133 
Despite that all studies addressed the same question – anti-IgE and its effectiveness in the 134 
treatment of food allergy – there was neither a systematic approaches to the outcomes nor an 135 
evaluation of the same allergen in the same conditions. Thereby, we performed a descriptive 136 
analysis where it was depicted and compared all outcomes of the included studies.  137 
This study also presents some limitations that may hamper its conclusions. First, although 138 
we have tried to broaden our search in order to find all the publish evidence, there is always 139 
some chance that some relevant studies have not been included. Although we have searched 140 
the evidence in all languages to avoid indexing errors, we have then excluded all non-english 141 
papers and some relevant studies might be excluded. Second, and more important, our 142 
revision might be subject to publication bias.
24
 It has been shown that systematic reviews 143 
performed when few studies are available, tend to overestimate effects, because ‘‘negative’’ 144 
studies are not published or face delayed publication. 
24
 It is possible that some studies, 145 
showing less extreme effects, remain unpublished and thus the observed benefit of anti-IgE 146 
may have been overestimated. The third limitation of our study results from the quality and 147 
amount of available evidence. The heterogeneity of the criteria used for the diagnosis of food 148 
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allergy, anti-IgE protocols used and outcomes reported limit the comparison of results and 149 
reinforces the need of more and better studies to elucidate this question.  150 
Further studies are needed to clarify the effectiveness of anti-IgE in the treatment of food 151 
allergy. More DBPCS with study population pooled by age, food allergen and severity of 152 
allergic symptoms would be particularly relevant. Also a specific anti-IgE protocol for food 153 
allergic patients (currently most patients are treated with the same protocols used for asthma) 154 
should be evaluated, since most of this food allergic patients present higher total and sIgE 155 
levels than asthmatic patients. Currently, there are three registered ongoing studies on this 156 
subject.  All these three studies are addressing peanut allergy. D. T. Umetsu et all 
25
, will 157 
perform a double blind, placebo controlled clinical trial multicenter study evaluating 158 
omalizumab as adjunctive treatment to OIT in patients with severe peanut allergy. W. Burks, 159 
26
, will perform a phase 2 randomized trial with Omalizumab in order to determine whether 160 
the addition of omalizumab will improve peanut OIT  safety. . R.A. Wood and S. Saini, 
27
, 161 
are evaluating omalizumab efficacy in  peanut allergy in a phase 2 non-randomized trial. 162 
In conclusion, although currently published studies support the concept that anti-IgE 163 
treatment is safe and has a beneficial role in food allergy and oral immunotherapy with foods, 164 
further and better designed studies are needed to elucidate the effectiveness of food allergy 165 
treatment with anti-IgE. 166 
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Table 1 Description of randomized-controlled trials (RCTs) 
 
Sampson 2011
16
 Leung 2003
17
 
Study design Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-
group trial 
Randomized, double-blind, placebo-controlled, dose-ranging study. 
n (active/control) 5/9 59/23 
Sex (F/M) 6/8 37/45 
Age  26.6 ± 22.5 placebo / 16.3 ± 11.1 active group 32.4 (13-59) 
Inclusion criteria Age: 6 – 75 years 
History of an immediate peanut allergy reaction after ingestion of food 
containing peanuts 
 
Positive double-blind, placebo-controlled OFC to peanut 
SPT positive to peanut extract and/or  peanut sIgE > 0.35 kUA/L 
Total IgE: 30-1330 IU/mL 
Body weight:  20-150 Kg   
Ability to perform reproducible spirometry 
Age: 12- 60 years 
History of peanut allergy (urticarial, angioedema, bronchospasm or 
hypotension) 
 
Positive double-blind, placebo-controlled OFC to peanut 
SPT positive for peanut and negative for tuna oil  
Total IgE: 30-1000 IU/mL 
Body weight within 20% of  ideal 
 
Exclusion criteria Tolerance to more than 250mg of peanut on OFC 
Reaction to any placebo on OFC 
Current treatment with specific immunotherapy  
Moderate persistent asthma and / or FEV1 < 80% predicted 
Treatment with daily  inhaled corticosteroids > 600 mcg of fluticasone in 
adults or > 400mcg of in children 
 
Use of oral or injected steroids within 30 days of the initial OFC 
History of brittle asthma chronic medical condition 
Any of any significant medical condition 
Pregnancy 
Uncontrolled asthma (FEV1<80%) 
Prior exposure to monoclonal antibodies 
 
Patients requiring medication with systemic corticosteroids, beta-blockers and 
acetylcholinesterases  inhibitors during study period 
Intervention 
Omalizumab (0,016mg/Kg/IgE(IU/mL) monthly for 24 week. If dose required 
greater than 300mg, dose was divided and given every 2 weeks 
TNX-901  (19 patients - 150mg; 19 - 300mg; 21 - 450mg),  monthly during  4 
months 
Control Placebo (0,016mg/Kg/IgE(IU/mL) monthly for 24 week. If dose required 
greater than 300mg, dose was divided and given every 2 weeks 
Placebo, monthly during  4 months 
Quality 
assessment* 
20/37 21/37 
 
FEV1 – Forced expiratory volume in 1 second; OFC – Oral Food Challenge; OIT – Oral Immunotherapy; SPT – Skin Prick Test; * - Quality 
assessment performed using CONSORT statement. 
 
Table 2 - Outcomes of randomized-controlled trials (RCTs) 
 
 Sampson 2011
16
 Leung 2003
17
 
Oral Food 
Challenge  
Threshold 
Limited data suggested an increase in tolerability to peanut flour in the 
omalizumab-treated versus placebo-treated subjects: 4 (44.4%) omalizumab-
treated subjects vs 1 (20%) placebo-treated subject could tolerate >_1000 mg 
peanut flour during an OFC after 24 weeks of treatment with study drug (p= 
0.324) 
 
Large proportion of subjects did not achieve the pre-specified tolerability: 5 
(55.6%) omalizumab-treated vs 4 (80%) placebo-treated subjects 
experienced reactions at <_1000 mg peanut flour. 
 
Change from baseline in maximum tolerable peanut dose after 24 weeks of 
treatment, there appears to be a greater shift in peanut tolerability in subjects 
treated with omalizumab for 24 weeks compared with placebo (p= 0.054). 
 
The mean threshold of sensitivity to peanut at the final oral food challenge 
increased from base line in a dose-responsive manner, but  only reached 
statistical significance for the 450-mg group (p<0.001). 
 
Proportion of patients who had an increase in the threshold of sensitivity of 
at least 0.9 log was greater in all the TNX-901 groups than in the placebo 
group, but was statistical significant only in the 450-mg group (P=0.002). 
 
Although pairwise comparisons with placebo of the proportions of patients 
who tolerated a given dose were not significant, significant trends with 
increasing dose were noted for the 4-g and 8-g threshold (p=0.02 for both). 
Skin prick 
tests 
Changes in SPT to peanut: Not reported Changes in SPT to peanut: Not reported 
 
Total and 
specific IgE 
Changes in specific IgE to peanut: Not reported 
Changes of total free IgE from week 2 to OFC 3: 
Omalizumab-treated group:  89 % (216.0 vs 4,24 IU/mL) 
 
Changes in specific IgE to peanut: Not reported 
Changes of total free IgE from baseline to week 4: 
Placebo-group  4 % (199,5 vs 207.4) 
150mg-group  88 %, (262.0 vs 30,4IU/mL) 
300mg-group   89 %, (158.9 vs 17,0IU/mL) 
450mg-group  93 %, (242.0 vs 16,6UI/mL). 
Safety Mild to moderate adverse events were reported in both groups during the 
treatment phase: placebo - 88.9%, and omalizumab - 76.5%. 2 mild adverse 
events were reported to omalizumab and none to placebo. 
 
Although the study intended to randomize 150 subjects, it was stopped early 
on the basis of the recommendation of the Data Safety Monitoring 
Committee because of the severity of 2 anaphylactic reactions during the 
qualifying oral food challenges (OFCs), before the administration of the 
study drug. Consequently, only 14 subjects reached the study’s primary 
endpoint before the interruption of the trial. 
The total number of systemic adverse events reported (45 to 50 per group) 
and the number of patients reporting adverse events (15 to 19 per group) 
were similar among the four groups. 
 
 
FEV1 – Forced expiratory volume in 1 second; OFC – Oral Food Challenge; SPT – Skin Prick Test; 4W – 4 weeks; 8W – 8 weeks. 
 
Table 3 - Description and outcomes non-randomized-controlled trials (non-RCTs.) 
 Henson 2012
23
 Savage 2012
22
 Nadeau 2011
20 
Rafi 2010
21 
n 6 14 11 22 
Sex (F/M) Not reported 11/3 4/7 13/9 
Age (range) >12 23 (18-44) 8 (7-17) 38 (14-66) 
Inclusion 
criteria 
History of significant clinical 
symptoms occurring within 
60minutes after ingesting peanuts 
 
Peanut sIgE >5KUA/L 
Positive SPT to peanut  
Age: 18 - 50 years 
Clinical history of early-onset 
peanut allergy 
 
Total IgE: 30 – 700 IU/mL 
Peanut sIgE >0.35 KUA/L 
Positive SPT to peanut 
Positive double-blind, placebo-
controlled OFC to peanut 
 
Peanut allergen–induced basophil 
histamine release > 
20% of total leukocyte content 
History of IgE-mediated milk 
allergy 
Elevated milk-specific IgE 
Patients treated with omalizumab 
for moderate to severe asthma with 
concomitant food allergies 
 
SPT positive to food before 
omalizumab treatment 
 
Unintended exposure to allergic 
food after initiation of omalizumab 
treatment  
Exclusion 
criteria 
History of severe anaphylaxis to 
peanut or omalizumab 
 
Currently participation in a study 
using an investigational n drug 
 
Participation in an interventional 
study for treatment of food allergy 
in the past 12 months 
 
Poor control of atopic dermatitis 
Moderate to severe persistent 
asthma 
Pregnancy   
Severe persistent asthma,  
FEV1 <80% of predicted  
Oral corticosteroid use for asthma 
in last 6 months 
 
History of severe allergic reaction 
to peanut requiring intensive care 
unit admission 
 
Late-onset peanut allergy 
 
Eosinophilic enteropathy. 
Not reported Not reported 
Intervention Omalizumab 4 months before  
initiation of OIT and continued for 
one month after reaching 
maintenance 
dosing. 
+ 
Omalizumab 
(0,016mg/Kg/IgE(IU/mL), monthly 
or bimonthly, depending on dose 
during 6 months. 
 
OFC at screening (OFC1), week 5 
Omalizumab 
(0,016mg/Kg/IgE(IU/mL), monthly 
or bimonthly, depending on dose 
during 16 weeks 
+ 
OIT initiated 9 weeks after 
Omalizumab(0,016mg/Kg/IgE(IU/
mL), monthly or bimonthly, 
depending on dose for at least 1 
year 
OIT (rush day(s), a build-up period, 
anda daily home maintenance phase 
with a final dose of 4000 mg of 
peanut protein. 
(OFC2) and week 24 (OFC3) 
 
omalizumab and continued until 
week 24 (2000 mg of milk protein 
is the target level at week 24). OIT 
in 2 phases: rush phase at day one 
in hospital; weekly dose escalation 
phase 
Control Not applicable Not applicable Not applicable  
Clinical 
symptoms 
All patients experienced symptoms 
on rush desensitization days:   
20/21 reactions were mild 
(comparable to previously 
published safety data for rush 
desensitization without 
omalizumab) 
 
Median peanut starting dose after 
rush desensitization with 
omalizumab was 300 mg (range 
100-400), higher than that seen 
without omalizumab pretreatment.  
 
On dose escalation days, 9.5% of 
doses (6 of 63) elicited symptoms in 
the omalizumab group, compared to 
43.3% of doses (123 of 284) in 
previous studies [RR 0.22 (95%CI 
0.10-0.48), p<0.0001]. . 
Only 10 patients the treatment 
period and the 3 scheduled OFC (1 
due to low FEv1 and 3 due to 
compliance issues) 
 All 22 patients reported a clinical 
improvement of food allergy, with a 
decrease or absence of clinical 
symptons after food ingestion: 
13 reduction of  food-induced 
asthma symptoms, 9 of sustemic 
symptoms, 8 of food-induced 
rhinosinusitis, 8 of food induced 
atopic dermatitis, 3 of food induced 
urticarial 
 
 
Oral Food 
Challenge 
Threshold 
  Increase of dose of peanut protein 
tolerated from baseline OFC to 
subsequent OITs (6.010 vs 212 vs 
212 mg; p<0.01) 
9 of 10  patients reached a daily 
dose of 2000 mg and all tolerated 
the DBPCFC 
and an open challenge at week 24. 
 
Skin prick test 
(SPT) 
 Reduction of Mean flare size from 
baseline: 
 18% at OFC 2 (p>0.05)  
 52% at OFC 3 (p<0.01)  
Changes not reported  
Total and sIgE  Changes not reported Changes not reported  
Other  Basophil histamine release: 
 88% from baseline at OFC 2 
  
(p<0.001) 
 75% from baseline at OFC 3 
(p<0,001)  
Safety  1 patient was unable to complete 
OFC2 and OFC3 because of low 
FEV1 
1 subject voluntarily discontinued 
the study due to abdominal 
migraines; eosinophilic esophagitis 
and other allergic disorders were 
ruled out. 
 
21 reactions  occurred during rush 
phase of OIT (14 mild, 5 moderate s 
and 2 severe) 
12 reactions occurred during 
weekly dose escalation phase (10  
mild, 1  moderate and 1 severe) 
The mean frequency for total 
reactions by week 24 was 1.6% (32 
reactions of 2199 doses total for all 
11 subjects). All patients 
experienced some adverse events, 
mostly mild (1%) needing no 
treatment. Moderate reactions 
occurred in 0.3% (requiring oral 
antihistamine) and severe reactions 
occurred in 0.1 % (only 1 patient 
required adrenaline injection). 
 
All subjects tolerated omalizumab 
treatment with no signs of allergic 
reactions. 
 
 
FEV1 – Forced expiratory volume in 1 second; MD maintenance dose; OFC – Oral Food Challenge; OIT – Oral Immunotherapy; sIgE – Specific 
IgE to food allergen; SPT – Skin Prick Test;  
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
 
Figure 1 - Study flowchart according to PRISMA.
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General Information 
 
The Annals of Allergy, Asthma & Immunology is the official journal of the American College of 
Allergy, Asthma and Immunology. The Annals acceptance rate is approximately 32%. Median 
turnaround time from submission to first decision is 22 days, from submission to acceptance is 
78 days, and acceptance to publication is 86 days.   
 
Editor-in-Chief:    Gailen D. Marshall, MD PhD 
Deputy Editor:   Mitchell H. Grayson, MD 
Managing Editor:  Kimberly K. Stamper, PMP 
 
Inquiries regarding the editorial management of the Annals should be sent to: 
 
Annals of Allergy, Asthma & Immunology  
Editorial Office 
2500 North State Street, Suite N416 
Jackson, MS 39216 
Telephone: (601) 815-4871 
Fax: (601) 815-4770 
Email: annallergy@umc.edu 
 
Authors are responsible for all statements, opinions, conclusions, and methods of presenting 
their data in articles submitted to the Annals of Allergy, Asthma & Immunology for possible 
publication. The views of authors as presented in their articles do not necessarily represent the 
opinions of the Annals of Allergy, Asthma & Immunology editorial staff or the American College 
of Allergy, Asthma and Immunology. 
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The purpose of these instructions is to provide authors with clear and concise guidelines for 
preparing a manuscript in acceptable Annals style. In general, exceptions to the published 
guidelines are not made. Authors who believe they have compelling reasons to alter and/or 
exceed the published guidelines may appeal to the editorial office for a variance PRIOR TO 
submission.  Appeals may be sent to annallergy@umc.edu. Otherwise, manuscripts that do not 
meet these guidelines will be returned to the corresponding author for revision prior to any 
further consideration for peer review.   
 
Editorial Policies for Authors 
 
Authorship   
It is assumed that a submitted manuscript is the work of the listed authors and represents the 
effort (data generation, accumulation and interpretation with subsequent manuscript writing) 
to generate the manuscript. While outside editorial assistance may be utilized, “ghost written” 
articles are not accepted for review by the Annals.  By submitting a manuscript the authors 
certify that they have (collectively) personally written at least 90 percent of the manuscript.  
Authorship credit should only be given when at least three of the following criteria are met: 
(1) conception and design of the study; (2) data generation (when applicable); (3) analysis and 
interpretation of the data and (4) preparation or critical revision of the manuscript. 
Additionally, all authors must approve the final version of the manuscript. If there are more 
than 5 authors, the contribution of each author must be substantiated on the title page.  
 
Acknowledgements  
All other persons who have made substantial contributions to the work reported in the 
manuscript (e.g., data collection, analysis, or writing or editing assistance) but who do not fulfill 
the authorship criteria may be named with their specific contributions in the Acknowledgments 
section,  provided the authors have written permission from each person.  
 
Role of the Corresponding Author 
The corresponding author will serve on behalf of all coauthors as the primary correspondent 
with the editorial office during the submission and review process. If the manuscript is 
accepted, the corresponding author will receive electronic page proofs from Elsevier, agrees to 
make only necessary changes and return the corrected page proofs to Elsevier within 48 hours 
of electronic receipt, even if you have no corrections. 
  
Conflicts of Interest and Financial Disclosures 
A conflict of interest may exist when an author (or the author's institution or employer) has 
financial or personal relationships that could potentially influence (or bias) the author's 
decisions, work, or manuscript. Potential conflicts of interest include, but are not limited to, 
speaker’s bureau membership, consultancies, research support and/or stock interest by an 
author and/or his/her first-degree relatives.  
 
All authors are required to complete section 5. Conflict of Interest and Financial Disclosures 
section of the Authorship Form at the time of submission. In this form, authors are to report 
potential conflicts of interest for the previous 12 months prior to submission of the manuscript.  
Authors without relevant conflicts of interest in the manuscript should indicate no such interest. 
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These conflicts of interest will be published in footnote form for all manuscripts accepted for 
publication by the Annals. Failure to comply with this requirement will result in the manuscript 
being returned without review. Click here to access the Authorship Form. 
 
Funding/Support  
All financial support for the research and the work should be clearly and completely identified 
on the title page. If no support was provided, please indicate so on the title page.  
 
Duplicate/Previous Publication or Submission  
Manuscripts are considered with the understanding that they have not been published 
previously in print / electronic format or in another language and that the manuscript is not 
under consideration by another publication or electronic medium.  
 
Ethical Approval of Studies and Informed Consent 
For all research studies involving animal or human subjects or research material derived from 
humans, appropriate institutional review board (IRB) review and approval is required and 
should be stated in the Methods section of the manuscript. The Annals will not publish human 
research which has not undergone IRB review.  For investigations involving human subjects, the 
manner in which informed consent was obtained from the study participants (i.e., oral or 
written) should also be stated in the Methods section of the manuscript. Studies exempted 
from IRB approval by their respective boards should be so indicated in the methods section. 
When reporting experiments on animals, authors should indicate whether the institutional and 
national guide for the care and use of laboratory animals was followed. Such review and 
approval or waiver should also be described in the Methods sections of the manuscript. Failure 
to comply with this requirement will result in the manuscript being returned without review. 
 
Clinical Trial Registration 
All manuscripts that present therapeutic data involving a pharmaceutical agent (commercial or 
non-commercial) must be registered with an approved Registry that meets the minimum 
registration data set as described by the International Committee of Medical Journal Editors 
(ICJME). Approved Registries include those listed below. 
 
1. www.anzctr.org.au  
2. www.clinicaltrials.gov  
3. www.ISRCTN.org  
4. www.umin.ac.jp/ctr/index/htm  
5. www.trialregister.nl  
 
The Registry URL and assigned database number should be clearly identified on the title page. 
 
Keywords 
Keywords are often an unappreciated tool by which authors can self identify the most salient 
categories and subcategories for their manuscript. The editorial staff uses these terms to find 
competent reviewers who have used the same keywords to identify their personal 
interest/expertise. A maximum of 12 keywords may be indicated during the submission 
process. 
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Reproduced Materials  
When previously published figures or tables are used, the author must obtain written 
permission from the copyright holder (usually the publisher) to reproduce the material in print 
and online. An appropriate credit line should be included in the figure legend or table footnote, 
and full publication information should be cited in the reference list. Letters of permission must 
accompany the manuscript at the time of submission. 
 
Revised Manuscripts 
Manuscripts may be returned to authors with request for revision. As with new submissions, 
revisions must be electronically submitted through the online manuscript submission and peer 
review system. Follow the instructions in the Author Tutorial (located on the home page) for 
submitting a revised manuscript. Revised manuscripts must 
 
1. Be received within one month of the date of the decision letter, 
2. Include a point-by-point response to all reviewer comments, and 
3. Text added to the revised manuscript should be highlighted and underlined in red, while 
strikethrough formatting should be applied to text that is  
being deleted. This same formatting principle applies to any table/figure  
revisions. 
 
The original text limits (word count, references, tables/figures) are still in effect. If the revision 
exceeds these limits, it will be the authors’ responsibility to fully explain why the revision 
cannot be edited to comply with the limits. This explanation should be provided in the response 
to the reviewers. Note: A revised manuscript not returned within one month of the date of the 
decision letter will automatically be rejected. Any further action will require an entire new 
submission process. Extensions to this deadline will be provided in extenuating circumstances 
and requires the prior approval of the Editor-in-Chief. 
 
Editorial Review and Publication 
 
Editorial Notification 
Corresponding authors are sent notifications of the receipt of manuscripts and editorial 
decisions by e-mail. Authors can check the status of their submitted manuscript, during the 
review process, via the online manuscript submission and peer review system. 
 
Editorial and Peer Review 
Manuscripts are initially reviewed by the Annals Editor-in-Chief. Manuscripts with insufficient 
priority for publication are declined and returned to the authors.  
Other manuscripts are assigned to an Associate Editor and sent to expert consultants for peer 
review. 
 
Editing 
Accepted manuscripts are edited in accordance with the AMA Manual of Style, 10th ed. and 
returned to the corresponding author for approval.   
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Proofs 
Corresponding authors will receive electronic versions of the page proofs for their articles from 
Elsevier. Authors should make only necessary changes and return the corrected page proofs to 
Elsevier within 48 hours, even if you have no corrections. If return of page proofs are delayed, 
the manuscript may at the discretion of the Editor-in-Chief be accepted for publication as is. 
Accurate proofreading and clear marking of corrections are essential for the production of a 
quality article. NOTE: Careful proofreading is solely your responsibility. Errata are generally 
not published for this oversight unless the error is significant.  
 
NIH Public Access Policy 
As a service to our authors, Elsevier will deposit to PubMed Central (PMC) author manuscripts 
reporting NIH funded research. Elsevier will send to PMC the final peer-reviewed manuscript, 
which was accepted for publication and sent to Elsevier’s production department, and that 
reflects any author-agreed changes made in response to peer-review comments. Elsevier will 
authorize the author manuscript’s public access posting 12 months after final publication. 
 
Reprints 
The Annals of Allergy, Asthma & Immunology makes available high quality reprints to its 
authors and the public. 
 
For commercial reprints please contact: 
 
 
Elsevier Inc. 
360 Park Avenue South 
New York, NY 10010-1710 
Tel: +1 212-633-3812 
Fax: +1 212-633-3820 
E-mail: reprints@elsevier.com 
 
For authors, the Reprint Order Form is sent with the electronic manuscript acknowledgment 
letter. Please complete the form and send the order form and purchase order or prepayment 
either by mail or fax to  
 
ANAI, Elsevier Philadelphia, Journals Production 
 
For the public, e-prints and reprints are available through Elsevier. For information and prices 
call Tel: +1 212-633-3812; Fax: +1 212-633-3820. 
Article Types  
 
The Annals publishes original articles, reviews, editorials, letters, correspondence and many 
other categories of articles. Topics of interest include all subjects that relate to the practice of 
allergy-immunology. The most frequent published types are described herein. 
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Original Articles 
Original articles should have a structured abstract of no more than 255 words with the 
following separate headings: Background, Objective, Methods, Results, and Conclusion.  A 
maximum of 12 keywords, 60 references, and a combined total of 8 tables and/or figures are 
allowed. Text should not exceed 4,000 words and should be organized into the following 
separate headings: Introduction, Methods, Results, and Discussion.  
 
Letters 
Letters are the primary means for an author to communicate brief clinical or scientific 
observations to our readership. Letters should NOT begin with the salutation “To the Editor”, 
are limited to 1,000 words, one figure OR table, and 10 references.   
 
Correspondence  
Correspondence are brief opinions about recently published articles in the Annals and other 
current topics of general interest to our readership.  Correspondence may or may not have a 
response, should begin with the salutation “To the Editor” and are limited to 500 words and 10 
references. Figures and tables are not allowed for this category. Correspondence submissions 
are reviewed in the Editorial Office and do not undergo outside peer review. Correspondence 
discussing a recently published Annals article will generally be considered only if it is received 
within 2 months of the article's publication date.  Exceptions to this policy must have the 
approval of the Editor-in-Chief. The previously published article should be cited in the text. 
 
Invited Articles 
 
The following article types require approval by the Editor-in-Chief before invitation. Authors 
who have an idea for one of these manuscript types are encouraged to submit a brief 
description to the Editor-in-Chief via email (annallergy@umc.edu).  Only those proposals that 
are approved by the Editor-in-Chief can be submitted and considered for publication. 
Exceptions to the guidelines for these features (i.e. word count, references, etc.) should be 
approved by the Editor-in-Chief prior to submission and be noted in the Author Comments 
section during the submission process. 
 
Review Articles  
Review articles address a specific question or issue that is relevant for clinical practice and 
provide an evidence-based, balanced, patient-oriented review on a focused topic, either clinical 
or basic science. Because of space limitations, the review is not intended to be exhaustive – it 
should be directed. These articles should focus on current advancements in the field, and 
should be based on the latest “cutting-edge” clinical, translational, or basic science.   
 
Review Articles should have a structured abstract of no more than 255 words with the following 
headings: Objective, Data Sources, Study Selections, Results, and Conclusion.  A maximum of 12 
keywords and 60 references are allowed. Text should not exceed 4,000 words and should be 
organized into the following sections: Introduction and Conclusion.  
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Pro-Con Debates 
Many clinical issues have conflicting approaches and opinions – both of which are typically 
evidence-based. This feature is designed to explore both sides of a specific issue which will  
allow the reader to consider various aspects to develop and improve personal approaches. Pro-
Con Debates do not have an abstract, and are subject to peer-review. Each author is allowed up 
to 1500 words to make one side of the argument; in addition, he/she may include up to 10 
references and 1 table or figure.  Since topics for debate are by nature controversial, cited 
references should emphasize recent publications. Unpublished data, including abstracts or "in 
press" manuscripts, should not be cited. When both manuscripts are acceptable, each author 
will be sent their opponent's manuscript and given 7 days to submit a rebuttal containing up to 
500 words; in addition, you may include up to 5 additional references at that time. New 
evidence should not be unfolded in the rebuttal. Instead, the rebuttal should consist of 
counter-arguments to the points advanced by the opponent in his or her primary manuscript. 
The listing and numbering of references in the rebuttal need to be independent of the initial 
portion of the manuscript. However, the two sides of the debate and rebuttal will be cited 
collectively after the Summary. The Annals Editorial Staff will prepare a brief Summary of the 
salient points to publish simultaneously with the debate. 
 
Perspectives 
On occasion, important topics of general interest to the readership are identified that warrant 
commentary and discussion by a specific expert. The Editor-in-Chief will invite such an expert to 
offer his/her perspective on a specific topic. Perspectives are limited to 2,000 words and 20 
references.  These articles do not have an abstract. 
 
MOC - CME Review  
MOC - CME Review articles offers physicians a process to keep skills and knowledge current in a 
changing field where vigilance is key to practicing state-of-the-art specialty medical care.  These 
articles are designed to help fulfill the requirements for CME credit required for the 
maintenance of certification (MOC) program by the American Board of Allergy and 
Immunology. Text should not exceed 2,000 words and should be organized into the following 
sections: Clinical Vignette (case presentation, up to 750 words), Introduction (a brief 
description of the pathophysiology fundamentals to the case, a clinical context of the case in 
terms of its uniqueness for the literature), and Conclusion (relevance to the practicing clinician 
including the principles of the case that would impact provider practice behavior).  A maximum 
of 12 keywords and 20 references are allowed, and articles must include 2 "behaviorally" 
written learning objectives.  A minimum of 5 multiple-part questions (with 5 answers each) 
related to the material must be included, along with a rationale and a maximum of 3 references 
for each question.  
 
Mechanisms of Disease for the Clinician  
Mechanisms of Disease for the Clinician articles are intended to update the readers with 
specific mechanism-based knowledge that is the basis for understanding the pathophysiology 
of a specific immune-based disease and/or a basis for understanding the effectiveness of a 
specific therapy.  These manuscripts should provide a brief overview of the current state of 
clinical knowledge, and then follow with a more in-depth discussion of the current 
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understanding of the molecular and cellular mechanisms that are thought to contribute to the 
disease and/or the basis for a specific therapy. Mechanisms of Disease for the Clinician articles 
should have a structured abstract of no more than 255 words with the following headings: 
Objective, Data Sources, Study Selections, Results, and Conclusion and are limited to 4,000 
words and 60 references.  
  
Editorials   
Guest Editorials are usually solicited to accompany certain special articles, CME review articles, 
and original articles that are published in the Annals. Text should not exceed 1,000 words and 
10 references. Guest Editorials should reference the previously published article in the Annals.  
 
CME Review Articles 
CME Review articles are offered as part of a Continuing Medical Education endeavor and are 
intended to be directed rather than exhaustive reviews of a specific clinical topic. The intent is 
to synthesize an overview of that topic with reference to the most current literature to allow 
the reader to better understand for the ultimate goal of changing practice behavior.  Text 
should not exceed 4,000 words and should be organized into the following sections: 
Introduction and Conclusion.  A maximum of 12 keywords and 60 references are allowed, and 
articles must include 2 "behaviorally" written learning objectives.  A minimum of 5 multiple-
part questions (with 5 answers each) related to the material must be included, along with a 
rationale and a maximum of 3 references for each question.  
 
Clinical Perspectives 
Clinical Perspectives are evidence-based reviews of topics relevant to the practicing 
allergist/immunologist.  Clinical Perspectives are limited to 2,000 words, 20 references, and a 
combined total of 8 tables and/or figures. Text should be organized into the following sections: 
Clinical Problem, Strategies and Evidence (to include evaluation and symptomatic versus 
specific therapy, when available), Areas of Uncertainty, Guidelines, and Conclusions and 
Recommendations. These articles do not have an abstract. 
 
Clinical Pearls  
Clinical Pearls focus on an unusual or unique physical finding, a diagnostic dilemma, or an 
unexpected clinical outcome. These are NOT classic case reports, rather a specific, point-by-
point communication that should provoke further clinical thought by the reader. Clinical Pearls 
are limited to a maximum of 1,000 words, 10 references, and a combined total of 8 tables 
and/or figures.  
 
Challenging Clinical Cases  
Challenging Clinical Cases consider the step-by-step process of clinical decision making. Cases 
are presented in stages (in boldface type) to simulate the typical way such information emerges 
in clinical practice. The author responds (in regular type) as new information is presented, 
sharing his/her reasoning with the reader. Challenging Clinical Cases are limited to 2,500 words, 
20 references, and a combined total of 8 tables and/or figures.  
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Book Reviews 
Short reviews of recently published books of central interest to our readers are published only 
by invitation from the Editor-in-Chief. Review text should not exceed 250 words and must 
include the title of the book, the author, publisher and address, edition and year of publication, 
availability in hard or soft copy, the number of pages, the price and ISBN #. Books for review 
should be sent to the Annals Editorial Office located at University of Mississippi Medical Center, 
2500 North State Street, N416, Jackson, MS 39216. 
 
Basic Science for the Clinician  
Basic Science for the Clinician reviews focus on a novel basic science research finding or 
technique.  These reviews should be concentrated on providing practicing clinicians an 
appropriate background on the science involved, followed by an explanation of the 
findings/techniques and how these findings/techniques may ultimately lead to changes in the 
clinic. Basic Science for the Clinician reviews should have a structured abstract of no more than 
255 words with the following headings: Objective, Data Sources, Study Selections, Results, and 
Conclusion.  Basic Science for the Clinician reviews are limited to 4,000 words and  60 
references.  
 
 
Manuscript Submission  
 
Manuscripts should be submitted online via the Annals of Allergy, Asthma & Immunology online 
manuscript submission and peer review system. NOTE: Only manuscripts submitted through 
this medium will be considered for review.   
 
Manuscript Preparation and Submission Requirements 
 
NOTE: Manuscripts that do not adhere to the following requirements will be returned to the 
corresponding author before peer review is initiated. 
 
Basic Formatting (Page Setup/Fonts) 
Each manuscript component, as described later in this document, should   
 
1. Be in a standard font such as Times New Roman, Arial, or Courier, size 12,    
2. Be attached as a separate submission item, 
3. Be double-spaced and have a one inch margin on all side, and 
4. Display page numbers in the upper right corner of each page and  
 continuous Line numbers (i.e., 1, 2, 3 etc.) in the left-hand margin of the  
 submission item. Do NOT restart numbering from each page. Line  
 numbering can be added from the File/Page Setup menu of word  
 processing programs and should be continuous throughout the manuscript  
 file, and  
5. Not contain brackets [ ] in the file names. 
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Article Lengths 
Authors must comply with text limits that have been established for each type of article. 
Articles of excessive length require prior approval from the Editor-in-Chief. Text limit excludes 
abstracts, acknowledgments, E-supplement material, figures, references or tables. Any variance 
approved by the Editor-in-Chief should be documented in the Comments section of submission 
process. 
 
Manuscript Submission items  
 
Submission Items 
Each submission must be comprised of the following submission items, unless otherwise 
specified:  a cover letter, title page, manuscript, references, a completed Authorship form for 
each author, and as appropriate acknowledgments, tables, figures, figure legend, CME Learning 
Objectives, CME Questions, CME Rationale and References, CME Honorarium form, Letters of 
Permission, and E-Supplement material. NOTE: Each component should be uploaded as a 
separate submission item unless otherwise specified. 
 
Cover Letter 
All manuscripts must be accompanied by a cover letter which includes the following: 
 
1. A statement to the editor that the manuscript has been read and approved by all the 
authors. 
2. A statement to the editor indicating the requirements for authorship as stated earlier in 
this document have been met.  
3. A statement to the editor that the authors certify that they have (collectively) personally 
written at least 90 percent of the manuscript. 
4. A statement to the editor that the manuscript has not been published previously in 
print/ electronic format or in another language and that the manuscript is not under 
consideration by another publication or electronic media. 
5. Complete contact information for the corresponding author, including a mailing address, 
telephone number, fax number, and e-mail address).  
 
Title Page  
The title page should be concise and easy to read and include the following: 
 
1. A concise title (no more than 15 words).  
2. Each author who meets authorship criteria should be listed, including the Author’s full 
name, abbreviated-highest academic degree, and institutional affiliation. 
3. The name, mailing address, telephone number, fax number, and e-mail address of the 
author responsible for correspondence. 
4. The source of any financial support.  If no support was provided, please indicate so on 
the title page. 
5. The Registry URL and assigned database number for clinical trial registrations. 
6. A word count for the manuscript (excluding abstract, acknowledgments, e-supplement 
material, figure legends, references and tables). 
7. The number of figures and tables accompanying the manuscript. 
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8. If there are more than 5 authors, the contribution of each author must be substantiated 
on the title page in context of the authorship criteria identified in the Editorial Policies 
for Authors section of this document.  
 
Manuscript 
In order to ensure a double-blind review, it is imperative that author identifying information 
not be included in the manuscript text. Abstracts, acknowledgments, E-supplement material, 
figures, references or tables should NOT be included in the manuscript text file. The text of 
the manuscript should be divided into sections with the following headings in this order, unless 
otherwise specified in Article Types section of this document.  
 
Introduction: Provide an overview of the scope and relevance of the study. 
 
Methods: Describe the design (randomized, double-blind, placebo control), subjects, setting 
(general community, private practice, and hospital), interventions, and main outcome 
measures.  For all research studies involving animal or human subjects or research material 
derived from humans, appropriate institutional review board (IRB) review and approval is 
required and should be stated in the Methods section. Studies exempted from IRB approval by 
their respective boards should also be indicated.  For investigations involving human subjects, 
the manner in which informed consent was obtained from the study participants (i.e., oral or 
written) should also be declared.  When reporting experiments on animals, authors should 
indicate whether the institutional and national guide for the care and use of laboratory animals 
was followed. Such review and approval or waiver should also be stated in the Methods 
sections of the manuscript  
 
Results: Describe the experimental data and results as well as the particular statistical 
significance of the data. 
 
Discussion: Provide and quantify the main outcomes of the study. Identify limitations of the 
presented data including plausible explanations for discrepancies between the data and the 
literature, any differences not expected from the initial hypothesis presented in the 
introduction and a measured description of the conclusions of the study with implications for 
future research, biological understanding and/or clinical applications.   
 
For guidance regarding grammar, punctuation, and scientific writing see the AMA Manual of 
Style, 10th ed. New York: Oxford Press; 2007.    
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Learning Objectives: At the conclusion of this activity, participants should be able to: 
 
• Describe the presentation of paradoxical vocal fold motion (PVFM). 
• Discuss the diagnostic tests that are best used to evaluate a patient with suspected 
paradoxical vocal fold motion (PVFM). 
 
Q1. Which of the following is true about paradoxical vocal fold motion (PVFM)? 
 
A. Response to rescue bronchodilator use   
B. Continuous symptoms   
C. Obstructive ventilatory impairment on spirometry during acute episodes 
D. Can be triggered by specific irritants  
E. Hypoxia with acute episodes 
 
Q1 ANS:  D  Can be triggered by specific irritants 
 
Rationale: 
Paradoxical vocal fold motion (PVFM) presents with symptoms that are often 
indistinguishable from asthma. Patients with PVFM without asthma typically have 
symptoms which occur on an intermittent basis, do not report response to asthma therapy 
including bronchodilator use, have spirometry evaluation without obstructive ventilatory 
impairment and are without hypoxia. Intrinsic irritants such as laryngopharyngeal reflux, 
postnasal drip or extrinsic irritants such as chemical exposure can trigger PVFM symptoms. 
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treatment. Laryngoscope. 2012;122:844–853. 
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